Abbott Laboratories reported strong Q4 2023 earnings, with year-over-year growth in EPS and revenue. The company's 2024 guidance projects further growth and improved ...

Abbott Laboratories ABT CEO Robert Ford, while speaking at the HLTH conference in Las Vegas, outlined the company's strategic move into the consumer wearables market. While Abbott has historically ...

The S&P 500 has performed well in 2023, but healthcare stocks have lagged behind. Abbott Laboratories continues to lap difficult comparable quarterly earnings reports, but the core business has been ...

The U. S. Department of Defense has awarded a $20 million contract to Abbott Laboratories to improve traumatic brain injury testing for military personnel, according to a Pentagon report. The report ...

Abbott Laboratories’ sales of COVID-19 tests fell by a whopping 89% during the second quarter of this year compared with the same time last year — a drop that comes as the world attempts to move on ...

Abbott Laboratories (NYSE:ABT) will release its quarterly earnings report on Wednesday, 2024-10-16. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Abbott ...

Lab personnel say worries are mounting over the safety of a rapid coronavirus test by Abbott Laboratories that President Donald Trump has repeatedly lauded ― particularly, the risk of infection to ...

Abbott Laboratories (NYSE:ABT) is preparing to release its quarterly earnings on Thursday, 2025-07-17. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...

CHICAGO (WLS) -- A new COVID19 test that provides results in five minutes is set to roll out soon as Illinois-based Abbott Labs expected to deliver 50,000 tests per-day. President Donald Trump did a ...

On Wednesday, Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying ...

An analyst from Barclays recently increased his price target for Abbott Laboratories to $143 per share. The raised target implies a gain of more than 30% from recent prices. A new collaboration with ...